Texas Children's

Texas Children's Hospital

nabil ahmed, MD - principal


donald parsons, md phd - co-site lead


meenakshi hegDe, md - investigator

Meenakshi Hegde is an Assistant Professor of Pediatrics in the Division of Hematology and Oncology at Texas Children’s Hospital and Baylor College of Medicine. Dr. Hegde completed her residency training at University of Illinois in Chicago followed by fellowship in Pediatric Hematology and Oncology at Baylor College of Medicine. Dr. Hegde is a physician-scientist with primary research focus on understanding the tumor adaptations and endogenous immune reactivity in response to CAR T-cell therapy with the intent to develop novel platforms for effectively targeting tumor-intrinsic escape and immune-inhibitory mechanisms for therapeutic applications. Her research findings to date have demonstrated that the landscape of antigen expression in glioblastoma and other solid tumors is highly heterogeneous, and that simultaneous targeting of these antigens improves tumor control by offsetting antigen escape. Dr. Hegde’s work was instrumental in developing multispecific CAR T cells for which she has received several fellowship and early career awards including the Schwiesguth Prize by the International Society of Paediatric Oncology (SIOP) and Young Investigator Award by the American Society of Pediatric Hematology-Oncology (ASPHO). Dr. Hegde’s clinical work spans translating new cellular therapies from the laboratory to the patients and rational development of combinatorial approaches for children with aggressive sarcomas and brain tumors.

khaled sanber, md phd - young investigator

Dr. Khaled Sanber is a clinical research fellow currently working on developing and improving novel cell-based immunotherapies against solid tumors. He is enrolled in the Medical Resident Investigator Track (MeRIT) at Baylor College of Medicine (BCM). He got his M.D. from the University of Jordan and his Ph.D. in Gene Therapy from University College London (UCL). His PhD work was aimed at facilitating the use of retroviral vectors in clinical application. In his current work at Meena Hegde’s and Nabil Ahmed’s labs, he uses different gene-editing techniques to modify T cells and enable them to mount an effective and sustained immune response against solid tumors.